NIDAMED News

Science Spotlight.

A new study looked at how well the FDA-approved nasal spray and autoinjector compared to the improvised nasal devices, which are not FDA-approved.

Science Spotlight.Some NIDA-funded scientists have just published findings in the journal Science showing the development of a new, groundbreaking chemogenetics technology for modulating brain function in a remote, precise and ultra-sensitive manner in living subjects.

NIDA-funded researchers identified a critical role for an internal brain opioid network called the dynorphin-kappa opioid receptor (KOR) system.

Science Spotlight.

The scientific world has advanced immeasurably by the science of DNA and genetics. Manipulating gene expression to change the way that cells such as neurons function has helped scientists create very specific tools to use for understanding and developing treatments for human diseases.

Study results on long-acting injection formulation now published.

A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection.

Science Spotlight.

A NIDA-funded analysis of eight states showed a significant association between rates of neonatal abstinence syndrome (NAS) and poor economic conditions.

Science Spotlight.

A team of NIDA-funded scientists has offered a critical look at how to build an improved framework of care for the identification and treatment of people with opioid use disorder (OUD).

As we enter 2019, it is a good time to take stock of what NIDA accomplished over the past year. As always when I look back at the research being done by NIDA grantees and partners, I am amazed at the wealth of knowledge being created from our investments. Here I want to highlight just a few of the many outstanding developments in basic science, new therapeutics, and epidemiology and prevention research from the year that just ended.

Opioid misuse at record lows with marijuana use remaining stable.

America’s teens report a dramatic increase in their use of vaping devices in just a single year, with 37.3 percent of 12th graders reporting “any vaping” in the past 12 months, compared to just 27.8 percent in 2017.

Media Advisory.

The National Institute on Drug Abuse (NIDA) will hold a teleconference on Monday, December 17, to discuss the results of the 2018 Monitoring the Future (MTF) survey.

Announcement.

The National Institutes of Health announced today that enrollment for the Adolescent Brain Cognitive Development (ABCD) Study is now complete and, in early 2019, scientists will have access to baseline data from all ABCD Study participants.

A recent analysis suggests that benzodiazepine use disorders are relatively rare among the adults who use benzodiazepine medications, even if they are misusing them.

Announcement.

The National Institute on Drug Abuse (NIDA) today announced the availability of informational resources for clinicians interested in initiating buprenorphine treatment in emergency department settings.

Nicotine does not produce the kind of euphoria or impairment that many other drugs like opioids and marijuana do. People do not get high from smoking cigarettes or vaping. Yet nicotine’s powerful ability to reinforce its relatively mild rewards results in 480,000 deaths annually.

The public health emergency of opioid misuse and addiction affects millions of Americans and requires innovative scientific solutions. Today, during “National Prescription Opioid and Heroin Awareness Week,” we are sharing news of an important step towards these solutions through the HEALing Communities Study.

Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who can prescribe these medications.

An analysis of health data concludes that e-cigarette use, adjusted for smoking conventional cigarettes and other risk factors, is associated with increased risk of myocardial infarction, which is commonly known as a heart attack caused by blockage of the arteries.

A NIDA-funded study has discovered that pregnant women in Appalachia face barriers to receiving medication-assisted treatment for opioid use disorders, from both insurers and providers.

Announcement.

The commentary, authored by Dr. Nora Volkow, director of the National Institute on Drug Abuse, and Dr. Martha Somerman, director of the National Institute of Dental and Craniofacial Research, both parts of the National Institutes of Health, highlights how the Institutes are working together to support scientific research for those in clinical practice.

Reducing healthcare’s reliance on potentially addictive opioid pain relievers has been one of the pillars of federal efforts to reverse the opioid crisis.

Announcement.

The National Institute on Drug Abuse (NIDA) Clinical Trials Network has unveiled a new scientifically validated, online screening tool designed to assess a patient’s risk for substance misuse and substance use disorder, and assist the health care provider with prevention and treatment strategies.

New online course is 10th in a series developed by the NIH Pain Consortium.

A case-based clinician training module designed for the evaluation of acute pain and opioid management for adults is now available through the Centers of Excellence in Pain Education (CoEPE) program, coordinated by the National Institute on Drug Abuse.

In this this NIDA-funded research, scientists used a novel approach to compare the cell signaling initiated by kappa opioids that produce dysphoria from those that do not.

Science Spotlight.

A comprehensive analysis of health insurance coverage of non-opioid and opioid medications to treat chronic low back pain concluded that some insurance plans have missed important opportunities to steer patients towards safer and more effective treatments than prescription opioids.

NIH research confirms effective treatments for opioid use disorder are underutilized.

A National Institutes of Health-funded study found that treatment of opioid use disorder with either methadone or buprenorphine following a nonfatal opioid overdose is associated with significant reductions in opioid related mortality.

In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving will go toward the goal of addressing addiction in new ways and better delivering existing forms of care to populations that need it.

Announcement.

The special issue is an overview of the ABCD Study and includes articles about the rationale for the study, its design and recruitment strategy, assessment protocols and neuroimaging parameters, the inclusion of twins in the research design, biomedical ethics and clinical oversight, and retention considerations, among others.

Study suggests that brain activity is not simply too high or low in people who are addicted to drugs, but behaves differently to drug and non-drug stimuli.

An animal study at NIDA’s intramural research labs suggests fentanyl-induced respiratory depression affects the temperature of the brain, triggering brain hypoxia and hyperglycemia.

Announcement.

Lofexidine, the first medication for use in reducing symptoms associated with opioid withdrawal in adults, has been approved by the U.S. Food and Drug Administration.